🇺🇸 FDA
Patent

US 12213990

A3 adenosine receptor ligand for use for achieving a fat loss effect

granted A61KA61K31/4706A61K31/4745

Quick answer

US patent 12213990 (A3 adenosine receptor ligand for use for achieving a fat loss effect) held by CAN-FITE BIOPHARMA LTD. expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CAN-FITE BIOPHARMA LTD.
Grant date
Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/4706, A61K31/4745, A61K31/7076, A61P